Roivant Sciences Ltd.
ROIV
$27.85
-$0.25-0.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 27.24% | -27.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 27.24% | -27.60% | |||
| Cost of Revenue | 1.16% | 7.61% | |||
| Gross Profit | -0.91% | -8.11% | |||
| SG&A Expenses | 35.15% | 1.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.15% | 4.60% | |||
| Operating Income | -16.09% | -4.85% | |||
| Income Before Tax | -82.57% | 40.93% | |||
| Income Tax Expenses | 233.55% | 50.46% | |||
| Earnings from Continuing Operations | -88.93% | 39.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -8.97% | 3.88% | |||
| Net Income | -134.23% | 49.18% | |||
| EBIT | -16.09% | -4.85% | |||
| EBITDA | -16.22% | -4.93% | |||
| EPS Basic | -128.91% | 49.22% | |||
| Normalized Basic EPS | -21.45% | -16.17% | |||
| EPS Diluted | -124.47% | 48.48% | |||
| Normalized Diluted EPS | -21.45% | -16.17% | |||
| Average Basic Shares Outstanding | 2.34% | 0.10% | |||
| Average Diluted Shares Outstanding | 2.34% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||